Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

337.72 -4.68 (-1.37%)

Streaming Delayed Price Updated: 1:40 PM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

61 62 Next >

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs ↗

January 25, 2024

The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.

Via InvestorPlace

What's Going On Johnson & Johnson Stock Today? ↗

January 24, 2024

JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch.

Via Benzinga

Topics Earnings

This 1 Bullish Move by Merck Could Drive Growth for Years to Come ↗

January 23, 2024

It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.

Via The Motley Fool

5 Magnificent Dividend Growth Stocks to Buy and Hold Forever ↗

January 23, 2024

These dividend growers ought to shine in 2024 and beyond.

Via The Motley Fool

Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning ↗

January 19, 2024

FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.

Via Benzinga

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

January 17, 2024

Via Benzinga

Why NASDAQ:AMGN is a Top Pick for Dividend Investors. ↗

January 12, 2024

Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN).

Via Chartmill

How Is The Market Feeling About Amgen? ↗

January 10, 2024

Via Benzinga

Looking At Amgen's Recent Unusual Options Activity ↗

January 09, 2024

Via Benzinga

Dividend Income Update December 2023 ↗

January 17, 2024

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.

Via Talk Markets

Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units ↗

January 16, 2024

On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.

Via Benzinga

Topics ETFs

Stocks Struggle As U.S. Dollar Sees Safety Bid ↗

January 16, 2024

Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors ↗

January 08, 2024

Via Benzinga

Looking At Amgen's Recent Unusual Options Activity ↗

January 05, 2024

Via Benzinga

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

Why Vera Therapeutics Stock Soared by 22% This Week ↗

January 12, 2024

Executive changes and a bullish analyst take combined to boost sentiment on the company.

Via The Motley Fool

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗

January 11, 2024

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the

Via Benzinga

AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗

January 11, 2024

AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.

Via Benzinga

Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains ↗

January 10, 2024

Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed.

Via InvestorPlace

Topics Stocks

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

Via Investor Brand Network

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END

Via FinancialNewsMedia

3 health care stocks off to strong starts in 2024

January 10, 2024

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

Via MarketBeat

Topics Artificial Intelligence

Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference ↗

January 10, 2024

Cramer shared his insights during his attendance at JPMorgan's healthcare conference,

Via Benzinga

Topics Artificial Intelligence

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

Via FinancialNewsMedia

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 08, 2024

Via Benzinga

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

From FN Media Group LLC

Via GlobeNewswire

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

A Rough Start To 2024 What Might Be In Store For The Rest Of 2024? ↗

January 07, 2024

The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year.

Via Talk Markets

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.